TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$73 Million

Sangamo Biosciences

Follow-on Offering

Lead Left Bookrunner, June 2017

Sangamo is a clinical stage biotechnology company focused on genomic medicines with the potential to transform patients’ lives using platform technologies in genome editing (both ex vivo cell therapy and in vivo), gene therapy and gene regulation. The Company is focused on three therapeutic areas: inherited metabolic diseases (IMDs), central nervous system (CNS) diseases and inflammatory and autoimmune diseases. Sangamo is a leader in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. Sangamo is developing its lead gene therapy asset, SB-525, with Pfizer for hem A which is currently being evaluated in a Phase I/II trial.